Serious adverse events (proportion) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · people with primary biliary cholangitis
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes serious adverse events (proportion) compared with UDCA (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events: nausea and vomiting · adults with refractory breathlessness
It is very uncertain whether the intervention changes adverse events: nausea and vomiting (very low certainty).
1 finding from 1 review
Adverse events PHQ‐9 questionnaire8 · People with common mental health disorders1
1 finding from 1 review
Serious adverse events (proportion) · people with major upper gastrointestinal, liver and pancreatic surgery
It is very uncertain whether enhanced recovery protocol changes serious adverse events (proportion) compared with standard care (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · patients with oesophageal cancer
It is very uncertain whether laparoscopic changes serious adverse events (proportion) compared with open transhiatal oesophagectomy (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · patients with pancreatic cancer
It is very uncertain whether laparoscopic distal pancreatectomy changes serious adverse events (proportion) compared with open distal pancreatectomy (very low certainty).
1 finding from 1 review
Intervention not reported
Clinically important adverse events · adults with schizophrenia or related disorders treated for clozapine‐induced tachycardia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Investigator‐defined adverse events · individuals with atrial fibrillation who are undergoing cardiac surgery
It is very uncertain whether the intervention changes investigator‐defined adverse events (very low certainty).
1 finding from 1 review
Adverse events Visual field defects · people with epilepsy
It is very uncertain whether VGB changes adverse events Visual field defects compared with CBZ monotherapy (very low certainty).
1 finding from 1 review